Contineum Therapeutics (CTNM) Accounts Payables (2023 - 2026)

Contineum Therapeutics' Accounts Payables history runs 4 years deep, the most recent figure standing at $505000.0 for Q2 2026.

• In Q2 2026, Accounts Payables fell 74.76% year-over-year to $505000.0; the TTM figure through Jun 2026 stood at $505000.0 (down 74.76% YoY), while the FY2025 annual figure was $1.0 million, down 43.9% from the prior year.
• Accounts Payables for Q2 2026 stood at $505000.0, down from $1.5 million in the prior quarter.
• The five-year high for Accounts Payables was $3.6 million in Q1 2025, with the low at $505000.0 in Q2 2026.
• The 4-year median for Accounts Payables is $1.0 million (2025), against an average of $1.3 million.
• The sharpest annual moves came in 2025 and 2026: Accounts Payables jumped 539.47% in 2025, then sank 74.76% in 2026.
• Contineum Therapeutics' Accounts Payables stood at $635000.0 in 2023, then soared by 185.2% to $1.8 million in 2024, then plunged by 43.9% to $1.0 million in 2025, then tumbled by 50.3% to $505000.0 in 2026.
• Business Quant data shows CTNM's Accounts Payables at $505000.0 in Q2 2026, $1.5 million in Q1 2026, and $1.0 million in Q4 2025.